Spectrum Pharmaceuticals Announces Second Quarter 2012 Financial Results Teleconference and Webcast
HENDERSON, Nev.--(BUSINESS WIRE)--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced it will host a
teleconference and webcast with management to discuss the second quarter
2012 financial results, provide an update on the Company's business, and
discuss expectations for the future.
|
Conference Call
|
|
|
|
|
|
|
|
|
|
|
|
Wednesday, August 8, 2012 @ 1:30 p.m. Eastern/10:30 a.m.
Pacific
|
|
|
|
|
|
|
|
|
|
|
|
Domestic:
|
|
|
|
|
|
(877) 837-3910, Conference ID# 14285827
|
|
|
|
|
|
|
|
|
|
|
|
International:
|
|
|
|
|
|
(973) 796-5077, Conference ID# 14285827
|
For interested individuals unable to join the call, a replay will be
available from August 8, 2012 @ 4:30 p.m. ET/1:30 p.m. PT through August
22, 2012 until 11:59 p.m. ET/8:59 p.m. PT.
|
Domestic Replay Dial-In #:
|
|
|
|
|
|
|
|
|
|
|
(855) 859-2056, Conference ID# 14285827
|
|
International Replay Dial-In #:
|
|
|
|
|
|
|
|
|
|
|
(404) 537-3406, Conference ID# 14285827
|
This conference call will also be webcast. Listeners may access the
webcast, which will be available on the investor relations page
of Spectrum Pharmaceuticals' website: www.sppirx.com on August
8, 2012 at 1:30 p.m. Eastern/10:30 a.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary
focus in oncology and hematology. Spectrum currently markets two
oncology drugs — FUSILEV® (levoleucovorin) for Injection in the
U.S. and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use,
for which the Company has worldwide marketing rights. Spectrum's strong
track record in in-licensing and acquiring differentiated drugs, and
expertise in clinical development have generated a robust, diversified,
and growing pipeline of product candidates in advanced-stage Phase 2 and
Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include but are not limited to statements
that relate to our business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, leveraging the expertise of partners and employees
around the world to assist us in the execution of our strategy, and any
statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical
fact. Risks that could cause actual results to differ include the
possibility that our existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new applications to
the FDA and other regulatory agencies may not receive approval in a
timely manner or at all, the possibility that our existing and new drug
candidates, if approved, may not be more effective, safer or more cost
efficient than competing drugs, the possibility that our efforts to
acquire or in-license and develop additional drug candidates may fail,
our lack of sustained revenue history, our limited marketing experience,
our dependence on third parties for clinical trials, manufacturing,
distribution and quality control and other risks that are described in
further detail in the Company's reports filed with the Securities and
Exchange Commission. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the information
contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of Spectrum
Pharmaceuticals, Inc. REDEFINING CANCER CARE™ and the Spectrum
Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals,
Inc.
© 2012 Spectrum Pharmaceuticals, Inc. All Rights
Reserved.
Spectrum Pharmaceuticals, Inc.
Shiv Kapoor, 702-835-6300
Vice
President, Strategic Planning & Investor Relations
InvestorRelations@sppirx.com
Source: Spectrum Pharmaceuticals, Inc.
News Provided by Acquire Media
Close window | Back to top
Delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz